WebJun 30, 2024 · The Phase III study was for Lumevoq, a gene therapy designed to fix Leber hereditary optic neuropathy, or LHON, a rare genetic disease that causes rapid vision loss in patients during adulthood. WebMar 21, 2024 · GeneSight Review Summary Overall, what GeneSight seeks to provide is a novel way for doctors to approach a wicked problem: the often lengthy and difficult process of identifying an appropriate …
Approval of GenSight’s gene therapy based on existing Phase III …
WebSep 15, 2024 · PARIS--(BUSINESS WIRE)-- Regulatory News:GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that the independent … WebFeb 5, 2024 · Sean Rai-Roche. GenSight Biologics’ Lumevoq (lenadogene neparvovec) drew expert caution about its approval prospects in Leber’s hereditary optic neuropathy (LHON) based on nebulous data from the first two of three Phase III trials. Results from two late-stage trials showed the gene therapy had an effect on the sham eye, and so data … glen campbell goodtime hour show
GenSight Biologics Announces the Publication of a …
WebDiagnosed with MDD, GAD and PTSD. when I first started seeing my psychiatrist a couple months ago, she gave me a GeneSight test. I started taking Trintellix per being in the “green light” section of my test and it seemed to work. Long story short, I got crappy about taking it and basically sent myself into a withdrawal and huge depressive ... WebMar 13, 2024 · The results show sustained efficacy and favorable safety for bilateral intravitreal injection of the gene therapy with a statistically significant visual acuity improvement from baseline in both treated eyes, showing an additional benefit of a bilateral injection compared to a unilateral injection. bodyline boots